Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 4Lymphoma, Non-Hodgkin 4Cytokine Release Syndrome 4Prostatic Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Renal Cell 2Thrombocytosis 1Thrombocytopenia 1Smoldering Multiple Myeloma 1Schwannomatosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pain 1Ovarian Neoplasms 1Neurilemmoma 1Neoplasms by Histologic Type 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × siltuximab × Clear all
NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Centocor, Inc.

Phase 1/2 Completed
84 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡